U.S. National Security & Business: Navigating Sanctions, Export Controls, CFIUS, and Outbound Investment Under the Trump Administration

Policy Shifts. Regulatory Risk. Investment Impact. What Every MedTech Legal Team Must Know in 2025

Join us to learn more about key developments in the national security context related to sanctions, export controls, CFIUS, and the new Outbound Investment Program, and how to issue spot and address the major issues confronting U.S. businesses and investors with respect to related transactions and investments.

Akin will provide a CLE program covering insights into the latest national security developments, including U.S. sanctions, export controls, CFIUS, and the new Outbound Investment Program, and how they affect medical technology companies. It will cover recent and anticipated policy changes under the Trump Administration, as well as the impact on foreign investment and strategic investments abroad. In covering these developments, we will also provide strategies medical technology companies can employ to assess and mitigate risk.  

Date: June 25, 2025
Time: 1:00 – 2:00 PM ET
Location: Online
CLE Sponsor: Akin Gump Strauss Hauer & Feld LLP
CLE Credit Hour: 1.

What You’ll Learn:

• An overview of U.S. sanctions and export controls policy, regulations, and enforcement, including recent and anticipated developments under the Trump Administration.
• An overview of developments addressing the CFIUS and the Outbound Investment Program, including a discussion of whether President Trump’s policies are making it easier or harder to accept foreign investment or to make strategic investments abroad.  

Who Should Attend

This is a must-attend session for legal professionals, compliance officers, and executives in the MedTech industry looking to stay ahead of trade policy changes and mitigate risks effectively.

• Company representatives involved in related international transactions 
• Medtech company in house counsel
• Trade compliance professionals

Date: June 25, 2025
Time: 1:00 – 2:00 PM ET
Location: Online

CLE Sponsor: Akin Gump Strauss Hauer & Feld LLP

CLE Credit Hour: 1.0

Pricing

AdvaMed® Member: Complimentary (FREE)
Non-AdvaMed® Members: $149 

Check to see if your company is an AdvaMed® member here. 

CLE Information

AdvaMed® Legal and Akin have an arrangement to bring virtual CLE sessions to AdvaMed® comany in house legal teams in 2025 addressing the cutting-edge legal issues in house medtech attorneys need to know in today’s environment. Akin will arrange the CLE. 
 
Akin is an accredited/approved CLE provider in California, New York, and Texas.  There are some states that offer reciprocity with these states:  Alaska, Arkansas, Connecticut, Florida, Hawaii, Montana, New Jersey, and North Dakota.   Akin’s procedure is to provide Uniform CLE Certificates of Attendance to attendees for other states to assist attending attorneys from other states in a self-application process. 

Meet Our Speakers

Katherine P. Padgett
Partner, Akin Gump Strauss Hauer & Feld LLP.

Katherine Padgett is a partner in Akin’s international trade practice, where she focuses on U.S. economic sanctions, export controls, and national security compliance. She regularly advises multinational corporations and financial institutions on navigating complex regulatory environments, including the International Traffic in Arms Regulations (ITAR), Export Administration Regulations (EAR), and Office of Foreign Assets Control (OFAC) sanctions. With deep experience conducting internal investigations, voluntary disclosures, and cross-border compliance reviews, Katherine helps clients develop practical strategies for managing legal risk in high-stakes transactions. Her expertise is particularly valuable to medical technology and healthcare companies facing increased scrutiny in global markets.

Jason Prince
Partner, Akin Gump Strauss Hauer & Feld LLP

Jason Prince is a partner at Akin and former Chief of Staff at the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC). He brings deep insight into U.S. sanctions policy, enforcement, and risk mitigation strategies. Jason advises clients on compliance with U.S. economic sanctions, anti-money laundering laws, and export controls, especially in complex cross-border transactions and investigations. Drawing on his senior government experience, he provides strategic counsel to multinational corporations, including those in the medical technology sector, on navigating fast-evolving national security challenges. Jason’s rare combination of public and private sector experience makes him a sought-after advisor on U.S. foreign policy and regulatory developments.

Opher Shweiki
Partner, Akin Gump Strauss Hauer & Feld LLP

Opher Shweiki is a partner in Akin’s international trade and regulatory practice, where he advises clients on foreign investment review, national security matters, and compliance with the Committee on Foreign Investment in the United States (CFIUS). He counsels U.S. and foreign companies on structuring transactions to address regulatory risk, especially in sensitive sectors like medical technology, critical infrastructure, and emerging technologies. Opher is known for guiding clients through complex CFIUS reviews and negotiations with government agencies, helping them achieve strategic business objectives while maintaining compliance. His experience extends to navigating the new outbound investment screening mechanisms under development in Washington.

Thomas Krueger
Senior Policy Advisor, Akin Gump Strauss Hauer & Feld LLP

Thomas Krueger is a senior policy advisor at Akin with deep expertise in U.S. economic policy, foreign investment, and sanctions. Prior to joining Akin, he served in senior roles at the U.S. Department of the Treasury, where he focused on national security and international finance. At Akin, Thomas advises clients on public policy developments impacting U.S. and international businesses, including CFIUS, the Outbound Investment Program, and geopolitical risk. His unique perspective bridges policy and legal strategy, making him a valuable resource for companies navigating evolving regulatory frameworks. He frequently collaborates with legal and compliance teams in the medical technology and investment sectors.